Management of extravasation of oxaliplatin by mimicking its biotransformation

[1]  M. McKeage,et al.  Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation , 2017, Scientific Reports.

[2]  S. Williamson,et al.  Guidelines for the Management of Extravasation , 2014 .

[3]  A. Margulies,et al.  Management of chemotherapy extravasation: ESMO--EONS clinical practice guidelines. , 2012, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[4]  T. Alcindor,et al.  Drug Development in Contemporary Oncology Methods of Study Selection , 2022 .

[5]  A. Weitberg,et al.  Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. , 2010, Oncology.

[6]  M. Palacios,et al.  Analytical methodologies for metallomics studies of antitumor Pt-containing drugs. , 2010, Metallomics : integrated biometal science.

[7]  A. Timerbaev,et al.  Interactions of Antitumor Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical Methodology , 2006 .

[8]  M. Styler,et al.  Extravasation of systemic hemato-oncological therapies. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  P. Boland,et al.  Case Report Vesicant Characteristics of Oxapliplatin Following Antecubital Extravasation , 2003 .

[10]  L. Rivory.  New drugs for colorectal cancer - mechanisms of action , 2002 .

[11]  A. Cailleux,et al.  Comparison of the reactivity of oxaliplatin, pt(diaminocyclohexane)Cl2 and pt(diaminocyclohexane1)(OH2)2(2+) with guanosine and L-methionine. , 2001, Journal of inorganic biochemistry.

[12]  A. Cailleux,et al.  Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[13]  M. Baur,et al.  Extravasation of Oxaliplatin (Eloxatin®) – Clinical Course , 2000, Oncology Research and Treatment.

[14]  S. Wyrick,et al.  Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. , 1998, Oncology research.

[15]  E. B. Skibo.  The Discovery of the Pyrrolo[1,2-a]benzimidazole Antitumor Agents - The Design of Selective Antitumor Agents , 1996, Current Medicinal Chemistry.

[16]  J. Roberts,et al.  Cross-linking of Complementary Strands of DNA in Mammalian Cells by Antitumour Platinum Compounds , 1972, Nature.